title: Identification of organoselenium compounds that possess chemopreventive properties in human prostate cancer LNCaP cells.
abstract: The process of cancer development consists of three sequential stages termed initiation, promotion, and progression. Oxidative stress damages DNA and introduces mutations into oncogenes or tumor suppressor genes, thus contributing to cancer development. Cancer chemoprevention is defined to prevent or delay the development of cancer by the use of natural or synthetic substances. In the present study, we synthesized a series of organoselenium compounds and evaluated their possible chemopreventive properties in human prostate cancer LNCaP cells. Among 42 organoselenium compounds tested, two compounds, 3-selena-1-dethiacephem 13 and 3-selena-1-dethiacephem 14 strongly activated the Nrf2/ARE (antioxidant response element) signaling and thus markedly increased expression of heme oxygenase-1 (HO-1), a phase II antioxidant enzyme. Translocation of Nrf2 to the nucleus preceded HO-1 protein induction by two compounds. The intracellular ROS level was strongly reduced immediately after treatment with these compounds, showing that they are potent antioxidants. Finally, both compounds inhibited cell growth via cell cycle arrest. Our findings suggest that compounds 13 and 14 could not only attenuate oxidative stress through Nrf2/ARE activation and direct ROS scavenging but also inhibit cell growth. Thus, these compounds possess the potential as pharmacological agents for chemoprevention of human prostate cancer.
authors.affiliation: Department of Longevity and Aging Research, Gifu International Institute of Biotechnology, 1-1 Naka-fudogaoka, Kakamigahara, Gifu 504-0838, Japan.
authors.forename: Riyako
authors.initials: R
authors.lastname: Terazawa
authors.forename: Dinesh R
authors.initials: DR
authors.lastname: Garud
authors.forename: Nanako
authors.initials: N
authors.lastname: Hamada
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Fujita
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Itoh
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Nozawa
authors.forename: Keita
authors.initials: K
authors.lastname: Nakane
authors.forename: Takashi
authors.initials: T
authors.lastname: Deguchi
authors.forename: Mamoru
authors.initials: M
authors.lastname: Koketsu
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ito
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D051547:Heme Oxygenase-1 / Q000096:biosynthesis / Q000378:metabolism; D006801:Humans; D008297:Male; D008968:Molecular Conformation; D051267:NF-E2-Related Factor 2 / Q000378:metabolism; D016566:Organoselenium Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; D016566:Organoselenium Compounds; D017382:Reactive Oxygen Species; C496541:HMOX1 protein, human; D051547:Heme Oxygenase-1